1 April 2019 - Advanced therapy medicinal products are beginning to reach European markets, and questions are being asked about their value for patients and how healthcare systems should pay for them.

An expert panel reviewed current HTA principles and practices in relation to the specific characteristics of advanced therapy medicinal products.

Three key topics were identified and prioritised for discussion—uncertainty, discounting, and health outcomes and value.

Read International Journal of Technology Assessment in Health Care article